Deriving Rare Disease Therapies from Human Plasma

Prometic Life Sciences is developing both plasma-derived and small molecule therapeutics to address a number of rare diseases that are today without therapies. Its lead experimental therapeutic is Ryplazim, which is purified human plasminogen that is being developed to treat congenital plasminogen deficiency. Plasminogen is a naturally occurring protein that plays a critical role in wound healing, cell migration, tissue remodeling, angiogenesis and embryogenesis. We spoke to Pierre Laurin, president and CEO of Prometic, about Ryplazim, the challenges and benefits of deriving products from human plasma, and what else is moving through the company’s pipeline.